Targeting TIGIT Inhibits Bladder Cancer Metastasis Through Suppressing IL-32
Bladder cancer is a highly metastatic tumor and one of the most common malignancies originating in the urinary tract. Despite the efficacy of immune checkpoints, including programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), the effect of immunotherapy for bladder...
Saved in:
Main Authors: | Kang Wu (Author), Jun Zeng (Author), Xulian Shi (Author), Jiajia Xie (Author), Yuqing Li (Author), Haoxiang Zheng (Author), Guoyu Peng (Author), Guanghui Zhu (Author), Dongdong Tang (Author), Song Wu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Functional Nanoparticles for Enhanced Cancer Therapy
by: Chenchen Li, et al.
Published: (2022) -
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
by: Peng Zhang, et al.
Published: (2024) -
AIM2 inflammasome activation benefits the therapeutic effect of BCG in bladder carcinoma
by: Houhong Zhou, et al.
Published: (2022) -
TGF-β induced reprogramming and drug resistance in triple-negative breast cells
by: Guoyu Wu, et al.
Published: (2022) -
Comparison of bladder carcinogenesis biomarkers in the urine of traditional cigarette users and e-cigarette users
by: Lida Feng, et al.
Published: (2024)